We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mortality and costs of acute renal failure associated with amphotericin B therapy.
- Authors
Bates, D W; Su, L; Yu, D T; Chertow, G M; Seger, D L; Gomes, D R; Dasbach, E J; Platt, R
- Abstract
To assess the mortality and resource utilization that results from acute renal failure associated with amphotericin B therapy, 707 adult admissions in which parenteral amphotericin B therapy was given were studied at a tertiary-care hospital. Main outcome measures were mortality, length of stay, and costs; we controlled for potential confounders, including age, sex, insurance status, baseline creatinine level, length of stay before beginning amphotericin B therapy, and severity of illness. Among 707 admissions, there were 212 episodes (30%) of acute renal failure. When renal failure developed, the mortality rate was much higher: 54% versus 16% (adjusted odds of death, 6.6). When acute renal failure occurred, the mean adjusted increase in length of stay was 8.2 days, and the adjusted total cost was $29,823. Although residual confounding exists despite adjustment, the increases in resource utilization that we found are large and the associated mortality is high when acute renal failure occurs following amphotericin B therapy.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Vol 32, Issue 5, p686
- ISSN
1058-4838
- Publication type
Journal Article
- DOI
10.1086/319211